Genprex
(NASDAQ: GNPX), a clinical-stage gene therapy company developing
potentially life-changing treatments for cancer and other serious diseases,
today announced that Dr. George Gittes, the lead researcher and Harvard
graduate that developed Genprex’s new potentially curative diabetes gene
therapy, was featured in a video interview discussing the therapy. According to
the update, Dr. Gittes joined one of Proactive’s broadcast journalists to
provide an overview of the gene therapy, how it works, how it may have the
potential to help treat type 1 and type 2 diabetes, as well as next steps to
move the gene therapy to the clinic. “We noticed that by gene therapy we could
cause some of the cells in the pancreas that do not normally make insulin, but
they are closely related to insulin cells, to turn into an insulin-producing
cell,” Dr. Gittes, Co-Scientific Director and Professor of Surgery at the UPMC
Children’s Hospital of Pittsburgh, said in the interview. “The real excitement
came when we realized that when we did this in a mouse that normally reacts to
its own insulin cells in the same way a juvenile diabetic or Type 1 diabetic
does, it didn’t notice these [new] cells and left them alone for a long time
without us doing anything else. It was just one treatment with a gene therapy,
and they [the mice] were fine for months, which is exciting.”
To watch the full video interview, visit: http://ibn.fm/z849F
To view the full press release, visit http://ibn.fm/GklUj
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing treatments for cancer and other serious
diseases. Genprex’s technologies are designed to administer disease-fighting genes
to provide new treatment options for large patient populations with cancer and
other serious diseases who currently have limited treatment options. Genprex
works with world-class institutions and collaborators to in-license and develop
drug candidates to further its pipeline of gene therapies in order to provide
novel treatment approaches for patients with cancer and other serious diseases.
The company’s lead product candidate, Oncoprex(TM) immunogene therapy for
non-small cell lung cancer (“NSCLC”), uses the company’s unique, proprietary
platform which delivers cancer-fighting genes by encapsulating them into
nanoscale hollow spheres called nanovesicles, which are then administered
intravenously and taken up by tumor cells where they express proteins that are
missing or found in low quantities. In January 2020, the FDA granted Fast Track
Designation for Oncoprex in combination with AstraZeneca’s Tagrisso(R) for the
treatment of NSCLC. For more information, please visit the company’s website
at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
